Nutex Health Inc. (NUTX) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed picture. While there are positive elements such as revenue growth in Population Health and strategic expansion plans, concerns arise from decreased gross profit margins and unclear management responses in the Q&A. Additionally, arbitration costs and revenue per visit issues could impact investor sentiment. The absence of strong positive catalysts like new partnerships or record high revenue, combined with mixed financial metrics, suggests a neutral stock price movement in the near term.
Key Financial Performance
Total Revenue $216.5 million, a 2% increase from $211.8 million in Q1 2025. The increase was driven by growth in both the Hospital division and Population Health division revenues.
Net Income $46.8 million, compared to $21.2 million in Q1 2025, reflecting a significant increase of $25.6 million. This improvement was attributed to operational efficiencies and revenue growth.
Adjusted EBITDA $57.6 million, down 21% from $72.8 million in Q1 2025. The decline was due to the timing of recognition for IDR expenses in the first quarter of 2025 compared to the same period in 2026.
Hospital Visits 49,700 total patient visits, up 3.1% from 48,300 patients in Q1 2025. The growth included a 0.6% increase from same hospitals, attributed to their resilience and relevance in their markets. A milder flu season in 2026 compared to 2025 also influenced the numbers.
Net Long-Term Debt Decreased from $29.2 million at December 31, 2025, to $24.3 million at the end of Q1 2026, reflecting a reduction in debt relative to revenue and expansion pace.
Net Cash from Operating Activities $75.5 million for Q1 2026, compared to $51 million in 2025, a 48% increase. This was driven by strong operational performance and revenue growth.
Cash on Hand $207.3 million as of March 31, 2026, up from $185.6 million at year-end 2025, reflecting an increase of $21.8 million or 11.7%.
Population Health Division Revenue $8.9 million in Q1 2026, up from $7.8 million in Q1 2025, representing a 14% increase. This growth was driven by an increase in managed care members and strategic expansion.
Gross Profit $91.7 million or 42.4% of total revenue in Q1 2026, compared to $118.3 million or 55.9% of total revenue in Q1 2025, reflecting a decrease in gross profit margin.
Operating Income $81.3 million for Q1 2026, compared to $80.7 million in Q1 2025, showing a slight increase of $0.6 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Service Lines: Developing and growing new service lines including medical detox programs, behavioral health sciences, outpatient imaging, outpatient procedures, and personal injury services.
Technology Investments: Investing in AI and IT to enhance patient care, streamline clinical workflows, and enable innovation within the micro hospital model.
Expansion of Hospital Facilities: Board approved direct investment in the development and construction of new hospital facilities, with plans to open 3 additional hospitals in San Antonio, Texas; Jacksonville, Florida; and West Little Rock, Arkansas in 2026.
Population Health Management: Overseeing a diverse group of almost 40,000 patients, with revenue growth in this division from $7.8 million in Q1 2025 to $8.9 million in Q1 2026.
Operational Efficiency: Improved patient retention, stronger clinical outcomes, and alignment of staffing models with real-time volume supported by centralized analytics.
Cost Management: Labor costs increased to $41.4 million, reflecting deliberate staffing decisions tied to demand. Medical supply costs increased modestly due to higher utilization.
Real Estate Strategy: Internalizing the development and construction of hospital facilities to reduce reliance on external credit markets and physician partners, with plans to monetize assets through sale-leaseback transactions.
Payer Strategy: Carefully evaluating in-network contract opportunities to ensure fair and equitable payment, aiming for comparable reimbursement to peer hospitals.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Adjusted EBITDA Decline: Adjusted EBITDA dropped by 21% from $72.8 million in Q1 2025 to $57.6 million in Q1 2026, primarily due to timing of recognition for IDR expenses.
Arbitration Costs: Arbitration costs increased significantly, representing 35% of arbitration-related revenue during the quarter, which is higher than the anticipated average of 24%-26%. This increase impacts profitability.
Operating Expenses: Operating expenses increased due to higher patient volumes, increasing acuity, and staffing investments. Labor costs rose to $41.4 million, representing 19.1% of net revenue.
Regulatory and Legislative Risks: The company is monitoring legislative developments, including the Murphy Bill and other legal decisions, which could impact operations and reimbursement strategies.
Dependence on IDR Process: The company relies heavily on the IDR process for claims, with 50%-60% of claims submitted through this process. While the success rate is high, this dependence poses a risk if regulatory or procedural changes occur.
Supply Chain Costs: Medical supply costs increased modestly due to higher utilization, though vendor standardization and group purchasing have mitigated pricing pressures.
Expansion Risks: The company is investing in new hospital facilities and internalizing real estate development. While this reduces reliance on external credit markets, it introduces risks related to capital allocation and execution of the development pipeline.
Technology Investments: Significant investments in AI and IT are being made to enhance patient care and operational efficiency. However, these investments carry risks related to implementation and achieving expected outcomes.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Future hospital openings: Nutex Health plans to open 3 additional hospitals in the third and fourth quarters of 2026, located in San Antonio, Texas; Jacksonville, Florida; and West Little Rock, Arkansas.
De novo pipeline strategy: The Board approved Nutex to directly invest in the development and construction of new hospital facilities. Once operational, these facilities will be monetized through sale-leaseback transactions with third-party owners, such as REITs. Proceeds will be reinvested into future developments to expand the company's footprint.
Technology investments: Nutex is investing in AI and IT to enhance patient care, streamline clinical workflows, and support innovation within its micro hospital model. These advancements aim to improve patient outcomes and drive sustainable patient volume growth.
Population Health Management growth: The company plans to expand its provider network, increase value-based contracts, and scale its analytics and care management platform to enhance its Population Health Management division.
Payer strategy: Nutex will continue to evaluate in-network contract opportunities and aims to ensure fair reimbursement for services. The company is monitoring legislative developments, such as the Murphy Bill, which could impact its payer strategy.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program Completion: In Q1 2026, Nutex Health completed its inaugural $25 million share repurchase program, retiring approximately 119,000 shares.
New Share Repurchase Program Initiation: During Q1 2026, Nutex Health initiated a second $25 million share repurchase program, reflecting management's confidence in the company's intrinsic value.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:When will the hospital development process initiated internally by Nutex start, and what is the expected balance sheet impact?
A:The process has already started with 3 new projects in Florida, which typically take 18 to 24 months to develop and open. Each project costs roughly $20 million to $30 million to build. Nutex plans to invest the down payments, secure financing, and flip the facilities to a REIT or long-term real estate vehicle upon opening. The balance sheet will initially reflect the land, building, and mortgage.
Q:Will the projects planned for 2027 include Florida?
A:No, the projects planned for 2027 will not include Florida as it is too soon. Nutex has 4 to 5 new projects planned for 2027, with half financed externally and the rest potentially financed by Nutex. Some projects have been in development for 6 to 12 months and are starting construction.
Q:What is the status of court cases and the Murphy Bill, and how does it affect negotiations with payers?
A:Nutex has had 3 positive court cases in California, Florida, and Pennsylvania, which are favorable for providers. However, the process with insurance companies remains challenging. Nutex is seeing better offers from insurance companies and continues to negotiate for in-network contracts.
Q:What is the explanation for the stock-based compensation being a negative number?
A:Stock-based compensation fluctuates based on the earnings of facilities in an earn-out, share price, and business value. Changes in these factors are accrued and finalized, which can result in positive or negative adjustments. In this case, the number decreased slightly due to these factors.
Q:What is the expected effective tax rate for the rest of the year?
A:The effective tax rate is expected to be in the high teens to 20%, consistent with the first quarter. Previous higher rates were due to permanent differences, which have now resolved.
Q:Why did arbitration costs increase to 35%, and when will they return to the mid-20% range?
A:Arbitration costs increased due to the accounting method, which records 100% of costs upfront while revenue is based on average collection rates. The percentage is expected to return to the mid-20% range over the next few quarters as the process stabilizes.
Q:Why did revenue per visit decline, and what is the outlook for this metric?
A:Revenue per visit declined slightly due to IDR award dynamics and payer mix. The metric is expected to stabilize around $4,000 to $4,200 per visit. Nutex is working on initiatives to increase acuity and improve reimbursement rates.
Q:What is the strategy for selective self-development of de novo facilities?
A:Nutex evaluates each location on a case-by-case basis to maximize shareholder value. The goal is to ensure a steady pipeline of 3 to 5 facilities per year while reducing costs and maintaining robust development.
Q:Why was patient volume growth only 3% year-on-year despite opening 3 hospitals last year?
A:Two hospitals opened in late December 2025 and one in January 2026, so they are still ramping up. Additionally, the flu season was less severe compared to the previous year, contributing to flatter volume growth.
Q:Can you quantify the revenue from the IDR process, and is the pivot towards higher acuity reflected in the numbers?
A:50% to 60% of claims are submitted through the IDR process, and the revenue from this is integrated into overall business numbers. The pivot towards higher acuity is reflected in consistent reimbursement rates and ongoing initiatives to improve acuity and realization.
Q:What is the long-term outlook for the Population Health segment?
A:The goal is to build networks of physicians around Nutex facilities to increase awareness and patient volume. While the L.A. IPA is the most profitable, other IPAs in Houston, Phoenix, and Miami are also profitable and growing. Expansion to Dallas and San Antonio is planned, with hospitals complementing these networks.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer to the specific timeline for arbitration costs returning to the mid-20% range, stating it would take another quarter or two without committing to a precise timeframe. Additionally, they did not provide a detailed breakdown of revenue from the IDR process, instead integrating it into overall business numbers.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Bamburg
Florida
Hospital division
Hosseinion
Relations Manager
analytics
area
awareness
capital
concierge level
confidence
contract
decision
determination
efficiency
estate
flu season
hand
hospital model
income period
infrastructure
investment
leverage
measurement period
micro hospital
month period
outcome
parallel
party
patient physician
physician partner
platform
pleasure
program
scalability
share repurchase
staffing
standardization
term value
utilization
value Health
NUTX Transcript
Nutex Health Inc. (NUTX) Q1 2026 Earnings Call Transcript
Unknown5-1
The earnings call summary presents a mixed picture. While there are positive elements such as revenue growth in Population Health and strategic expansion plans, concerns arise from decreased gross profit margins and unclear management responses in the Q&A. Additionally, arbitration costs and revenue per visit issues could impact investor sentiment. The absence of strong positive catalysts like new partnerships or record high revenue, combined with mixed financial metrics, suggests a neutral stock price movement in the near term.
Nutex Health Inc. (NUTX) Q4 2025 Earnings Call Transcript
Positive3-6
The earnings call reveals strong financial performance with an 82% revenue increase and a $25 million share repurchase program, indicating shareholder value focus. Despite reimbursement challenges, the company shows resilience with improved cash flows and debt management. The Q&A section highlights strategic expansions and positive trends in IDR processes, although management's unclear responses on true-up adjustments may cause slight concern. Overall, the strong financial metrics and optimistic expansions outweigh the negatives, suggesting a positive stock price movement.
Nutex Health Inc. (NUTX) Q2 2025 Earnings Call Transcript
Positive8-25
The earnings call summary reveals strong financial performance with significant revenue growth, improved net income, and efficient cash management. Despite some concerns in the Q&A about delayed audited results and lower EBITDA margins, the company's overall trajectory is positive, driven by successful arbitration efforts, new hospital openings, and optimistic management guidance. The consistent revenue growth and robust cash position suggest a favorable stock reaction, likely in the positive range of 2% to 8%.
Nutex Health Inc. (NUTX) Q1 2025 Earnings Conference Call Transcript
Unknown5-14
The earnings call summary presents a mixed picture: strong revenue growth, improved EBITDA, and cash flow are positives, but rising labor costs and competition pose risks. The Q&A reveals management's reluctance to provide clear guidance, which may concern investors. While financial performance is strong, uncertainties in future predictability and competitive pressures balance the sentiment, leading to a neutral stock price outlook.
NUTX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
